BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37175412)

  • 21. p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
    Meng J; Qian W; Yang Z; Gong L; Xu D; Huang H; Jiang X; Pu Z; Yin Y; Zou J
    BMC Cancer; 2024 Mar; 24(1):317. PubMed ID: 38454344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide.
    Xu X; Zheng Y; Luo L; You Z; Chen H; Wang J; Zhang F; Liu Y; Ke Y
    Cell Death Dis; 2024 May; 15(5):318. PubMed ID: 38710703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    Yu J; Gao G; Wei X; Wang Y
    BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
    Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH
    Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma.
    Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D
    J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
    Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
    BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics.
    Chen H; Li C; Hu H; Zhang B
    BMC Mol Cell Biol; 2022 Aug; 23(1):38. PubMed ID: 35982414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).
    Xu J; Song J; Xiao M; Wang C; Zhang Q; Yuan X; Tian S
    Bioengineered; 2021 Dec; 12(2):11768-11781. PubMed ID: 34895074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
    Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma.
    Lin HY; Liao KH; Ko CY; Chen GY; Hsu SP; Hung CY; Hsu TI
    Free Radic Biol Med; 2021 Aug; 172():430-440. PubMed ID: 34186205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
    Zhao K; Schäfer A; Zhang Z; Elsässer K; Culmsee C; Zhong L; Pagenstecher A; Nimsky C; Bartsch JW
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
    Zhao W; Yun K
    Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
    Zhou L; Huang X; Zhang Y; Wang J; Li H; Huang H
    Brain Behav; 2022 May; 12(5):e2531. PubMed ID: 35380741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
    Tian T; Mingyi M; Qiu X; Qiu Y
    Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.